Antibody ID	ANTI0KSFMQ
Antibody Name	CD33-11A1-v1417-LCQ05-H16-K222R-hG1
Synonyms	CD33-11A1-v1417-LCQ05-H16-K222R-hG1    Click to Show/Hide
Antigen Name	Myeloid cell surface antigen CD33 (CD33)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.69 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.6 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	156 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	196 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.29 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	69.14 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4970 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.86 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	47.53 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	669 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.51 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.8 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.28 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	60.76 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Ref 1	Calicheamicin derivatives and antibody drug conjugates thereof